Avalanche Biotechnologies Header Image: Iris
Sustained Therapeutic delivery for the eye

Contact Us

To learn more about Avalanche and our therapies for treating eye-related diseases, contact us.

Avalanche Biotechnologies
1035 O’Brien Drive, Suite A
Menlo Park, CA 94025

Tel: 650-272-6269
Fax: 650-362-1908

Email:

General Inquiry: info@avalanchebiotech.com
Careers: careers@avalanchebiotech.com
Business Development: busdev@avalanchebiotech.com


Or Submit This Contact Form:

Send To:
First Name:*
Last Name:*
Title:
Company Name:*
E-mail Address:*
Phone Number:
Message:*
 

Avalanche Biotechnologies to Present at the Ophthalmology Innovation Summit at the American Academy of Ophthalmology 2014 Annual Meeting

October 9, 2014

MENLO PARK, CA – October 9, 2014 – Avalanche Biotechnologies, Inc. (Nasdaq: AAVL), a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic diseases, today announced that Thomas W. Chalberg, Jr., Ph.D., Founder and Chief Executive Officer, will present at the Ophthalmology Innovation Summit at the American Academy of Ophthalmology 2014 Annual Meeting on Thursday, October 16, 2014 at 8:49 am CDT in Chicago, IL. Additionally, Dr. Chalberg will participate in the “IPOs in Ophthalmology – The Class of 2014 and Beyond” at 4:10 pm CDT.

Read More

Read All Avalanche News